Floatz logo

Sorafenib

Pediatric Solid Tumors

Washington University School of MedicineSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pediatric Solid Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
Washington University School of Medicine
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 1/2CCC
Temsirolimus
Memorial Sloan Kettering Cancer Center
Phase 1CC
Perifosine
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →